CSL Ltd Annual Report 2020

5. Executive Key Management Personnel Outcomes in 2020 5.1 CSL Performance 2020 has been another year of outstanding performance outcomes. Financial performance has been strong and we continue to develop and progress our research and development pipeline, consistently innovating to ensure a sustainable business. Our new end to end supply chain model continues to be implemented enabling an efficient and reliable supply. CSL has been on the forefront in the response to the COVID-19 pandemic. As the pandemic evolved, CSL continued to provide an uninterrupted supply of our medicines around the world. Our team is working with academia, industry and governments globally to combat the novel coronavirus COVID-19. The following performance outcomes, as aligned to the CSL strategy, were achieved resulting in an average overall STI payment outcome of 122% of target level opportunity across the Executive KMP (see Table 3). The minimum STI earned as a percentage of target level opportunity was 118% and the maximumwas 126% – the latter was 84% of the maximum STI outcome that could be achieved. Additional quantitative objectives, which were also integral to the achievement of individual performance, were considered by the Board when assessing Executive KMP performance. However, these remain confidential for commercial reasons. Table 2: CSL Achievements in 2020 Strategy Component Rating Outcome Financial NPAT ● • Reported NPAT above target at US$2,102.5m CFO ● • Reported CFO above target at US$2,488.3m People ● • CSL named in the Top 500 companies for Diversity in the US by Forbes • Continued employee engagement scores above the global norm • Key leadership appointments following organisational operating structure review Focus ● • Agreement for a primary immunodeficiency gene therapy collaboration with the Seattle Children’s Research expanding our cell and gene therapy footprint into the Immunology Therapeutic Area • Acquisition of Vitaeris Innovation ● • HIZENTRA ® granted Orphan Drug Exclusivity for CIDP • HIZENTRA ® Dermatomyositis Phase III study initiated • CSL112 trial (cardiovascular disease) Phase III progressing • CSL200 first patient with sickle cell disease dosed • US FDA approval of AUDENZTM – world’s first adjuvanted, cell-based influenza A (H5N1) pandemic vaccine • FLUCELVAX ® launched in EU • FLUAD ® preferred recommendations in UK and Australia, and QIV approved in Australia • Positive real world effectiveness evidence continuing for FLUCELVAX ® and FLUAD ® • Commenced aQIVc development Efficiency and Reliable Supply ● • 40 plasma collection centres opened taking our total to 277 globally • Operationalisation of our new End to End Supply Chain model • Successful implementation of the final phase of the new Enterprise Resource Planning system in Asia Pacific – the system is now fully implemented globally • Major capital projects at all manufacturing sites progressing to support future demand • Transition to Good Supply Practices (GSP) license in China Sustainable Growth ● • Global expansion with two new offices opening (Saudi Arabia and Colombia) • Strategic partnership with Thermo Fisher Scientific for the lease of CSL’s Lengnau biotech manufacturing facility ● Target Exceeded ● Target Met ● Target Partially Met ● Target Not Met CSL Limited Annual Report 2020 77